Benzodiazepine receptor quantification in Huntington's disease with [123I]iomazenil and SPECT

• Published in: Journal of neurology, neurosurgery and psychiatry Vol. 70; no. 5; pp. 657 - 661
• Main Authors: Pinborg, L H, Videbæk, C, Hasselbalch, S G, Sørensen, S A, Wagner, A, Paulson, O B, Knudsen, G M
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.05.2001; BMJ; BMJ Publishing Group LTD; BMJ Group
• Subjects: benzodiazepine receptor; Benzodiazepines; Biological and medical sciences; Cell death; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Diagnosis; Huntington's chorea; Huntington's disease; Huntingtons disease; Medical sciences; Metabolism; Metabolites; Mutation; Neurology; Oxidative stress; Patients; Plasma; SPECT imaging; SPECT-iomazenil; United States; Radionuclide study; Human; Nervous system diseases; Pathophysiology; Central nervous system; Huntington disease; Benzodiazepine receptor; Iomazenil(123I); Photon; Cerebral disorder; Genetic disease; Central nervous system disease; Degenerative disease; Extrapyramidal syndrome; Brain (vertebrata); Emission tomography

OBJECTIVES Increasing evidence suggests that metabolic changes predate neuronal death in Huntington's disease and emission tomography methods (PET and SPECT) have shown changes in glucose consumption and receptor function in early and possibly even presymptomatic disease. Because the GABAA-benz...